Iberia Pharmaceuticals India Ltd.
BSETBA
TBA
1 Shares
TBA
₹10
Financial Summary
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| 9,653.7 | 8,672.1 | |
| 171.36 | 44 | |
| 9,825.06 | 8,716.1 | |
| 7,951.2 | 6,434.59 | |
| 1,515.22 | 1,954.21 | |
| 1,113.49 | 1,419.13 |
Subscription Details
IPO Timeline
IPO Offer Start
TBA
IPO Offer Ends
TBA
TBA
Use of Proceeds
| # | Purpose | Amount (₹ Million) |
|---|---|---|
| 1 | Capital expenditure towards the procurement of plant & machinery for the | 348.951 |
| 2 | Repayment of all or a portion of certain outstanding borrowings availed by our | 120 |
| 3 | Branding and marketing expenses towards enhancing the awareness and | 169 |
| 4 | Funding the working capital requirements of our Company | 310 |
Promoters
Book Running Lead Managers
Promoter Shareholding
Pre-IPO
97.59%
Promoter stake
Offered to Public
64,75,560
shares
About the Company
We are an Indian pharmaceutical and derma cosmetics company with a select portfolio of products across aesthetic dermatology, hair care, cardio diabetic and general therapeutics, offering solutions for a wide range of skin, hair, cardiovascular, diabetic and anti-aging concerns. Our products comprise pharmaceutical products, including drugs requiring prescriptions from healthcare professionals, as well as derma cosmetic products and other over-thecounter solutions for healthcare and aesthetic use. India’s aesthetic dermatology market has become one of the fastest-expanding sectors in healthcare and beauty. Valued at USD 620 million in CY25, it is projected to reach USD 1,274 Million by CY31, driven by increasing awareness of skin health, societal shifts, and the growing popularity of minimally invasive treatments. Once considered a niche, aesthetic dermatology is now widely accepted across diverse demographics, including millennials and men.
Use of Proceeds
1. Capital expenditure towards the procurement of machinery for the establishment of our manufacturing facility in Haryana, India 2. Repayment of all or a portion of certain outstanding borrowings availed by our Company. 3. Branding and marketing expenses towards enhancing the awareness and visibility of our products and brand; 4. Funding the working capital requirements of our Company; 5. General Corporate Purposes.
Iberia Pharmaceuticals India Ltd. Latest News
News
No news found for Iberia Pharmaceuticals India Ltd..